| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF00315023 |
| P698 | PubMed publication ID | 2340843 |
| P2093 | author name string | K Wagner | |
| W Weber | |||
| J Brockmöller | |||
| H H Neumayer | |||
| I Roots | |||
| G Heinemeyer | |||
| H Kewitz | |||
| P2860 | cites work | Cyclosporine drug interactions: a review | Q39688566 |
| Clinical pharmacokinetics of cyclosporin | Q39729593 | ||
| Role of calcium in pathogenesis of acute renal failure | Q39731204 | ||
| Trough levels and concentration time curves of cyclosporine in patients undergoing renal transplantation | Q41293301 | ||
| On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers | Q42655150 | ||
| Cyclosporin-verapamil interaction | Q43229099 | ||
| Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily | Q43422277 | ||
| Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil | Q49039298 | ||
| Noncompartmental determination of the steady-state volume of distribution for any mode of administration. | Q52724350 | ||
| Standardization of symbols in clinical pharmacology | Q68021709 | ||
| Prevention of posttransplant acute tubular necrosis by the calcium antagonist diltiazem: a prospective randomized study | Q68209396 | ||
| Measurement of cyclosporin A and of four metabolites in whole blood by high-performance liquid chromatography | Q68963439 | ||
| Prevention of delayed graft function in cadaver kidney transplants by diltiazem: outcome of two prospective, randomized clinical trials | Q69030886 | ||
| Immunosuppressive properties of cyclosporin metabolites | Q69368328 | ||
| Cyclosporin drug monitoring: comparison of four immunoassays and HPLC | Q69503922 | ||
| Cyclosporin. Pharmacokinetics and metabolism | Q69555925 | ||
| Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrine | Q69567235 | ||
| Biotransformation and distribution in blood of cyclosporine and its metabolites | Q69677371 | ||
| Nephrotoxic and immunosuppressive potentials of cyclosporine metabolites in rats | Q69677381 | ||
| Prevention of delayed graft function in cadaver kidney transplants by diltiazem | Q69873550 | ||
| Cyclosporin-diltiazem interaction | Q69880635 | ||
| Influence of diltiazem on cyclosporin clearance | Q69882360 | ||
| Nicardipine increases cyclosporin blood levels | Q69882455 | ||
| Diltiazem and economic use of cyclosporin | Q69886129 | ||
| In vitro immunosuppressive properties of cyclosporine metabolites | Q70020765 | ||
| Anaphylactic reaction and cardiopulmonary arrest following intravenous cyclosporine | Q70055582 | ||
| A program for non-linear regression analysis to be used on desk-top computers | Q70823942 | ||
| A Radioimmunoassay to Measure Cyclosporin a in Plasma and Serum Samples | Q70946075 | ||
| P433 | issue | 3 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 237-242 | |
| P577 | publication date | 1990-01-01 | |
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | Pharmacokinetic interaction between cyclosporin and diltiazem | |
| P478 | volume | 38 |
| Q70555092 | A controlled, double-blind, randomized trial of verapamil and cyclosporine in cadaver renal transplant patients |
| Q73881251 | A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients |
| Q35846658 | Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients |
| Q40648534 | Assessment of liver metabolic function. Clinical implications |
| Q36699356 | Calcium Antagonists in Patients with Heart Failure |
| Q35166632 | Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. |
| Q41676632 | Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers |
| Q35709872 | Drug therapy in transplant recipients: special considerations in the elderly with comorbid conditions |
| Q42545396 | Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients |
| Q36053886 | Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients |
| Q45262401 | Evaluation of hepatic function using the pharmacokinetics of a therapeutically administered drug. Application to the immunosuppressant cyclosporin |
| Q36055276 | Intravenous diltiazem and CYP3A-mediated metabolism |
| Q71835960 | Is the beneficial effect of calcium channel blockers against cyclosporine A toxicity related to a restoration of ATP synthesis? |
| Q77449564 | Is there a beneficial effect of the calcium channel blocker diltiazem on cyclosporine A nephrotoxicity in rats? |
| Q36068699 | Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. |
| Q38018027 | Pharmacokinetic drug interactions with cyclosporin (Part II). |
| Q71674668 | Pharmacokinetic interaction between diltiazem and nortriptyline |
| Q67575638 | Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate |
| Q77495508 | The interaction of diltiazem with lovastatin and pravastatin |
| Q41478142 | The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations |
| Q34345648 | Trough concentrations of cyclosporine in blood following administration with grapefruit juice |
Search more.